Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study by Dieckmann, Klaus-Peter et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of
Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Dieckmann, Klaus-Peter; Radtke, Arlo; Geczi, Lajos; et al; Hermanns, Thomas; Fankhauser, Christian
Daniel
Abstract: PURPOSE Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called
M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell
tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the
usefulness of this test as a novel biomarker for GCT. PATIENTS AND METHODS In a prospective,
multicentric study, serum samples of 616 patients with testicular GCTs and 258 male controls were
examined for serum levels of miRNA-371a-3p (miR levels) by quantitative polymerase chain reaction. The
GCT population encompassed 359 patients with seminoma and 257 with nonseminoma; 371 had clinical
stage I disease, 201 had systemic disease, and 46 had relapses. Paired measurements before and after
orchiectomy were performed in 424 patients; 118 with systemic disease had serial measurements during
treatment. miR levels were compared with those of ￿-human chorionic gonadotropin, ￿-fetoprotein, and
lactate dehydrogenase. RESULTS For the primary diagnosis of GCT, the M371 test showed a sensitivity
of 90.1%, a specificity of 94.0%, an area under the curve of 0.966 upon receiver operating characteristic
analysis, and a positive predictive value of 97.2%. ￿-Fetoprotein, ￿-human chorionic gonadotropin, and
lactate dehydrogenase had sensitivities of less than 50% in seminoma and slightly higher sensitivities
in nonseminomas. miR levels were significantly associated with clinical stage, primary tumor size, and
response to treatment. Relapses had elevated miR levels that subsequently dropped to normal upon
remission. Teratoma did not express miR-371a-3p. CONCLUSION The M371 test outperforms the classic
markers of GCT with both a sensitivity and a specificity greater than 90%. All histologic subgroups,
except teratoma, express this marker. The test could be considered for clinical implementation after
further validation.
DOI: https://doi.org/10.1200/JCO.18.01480
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-170720
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Dieckmann, Klaus-Peter; Radtke, Arlo; Geczi, Lajos; et al; Hermanns, Thomas; Fankhauser, Christian
Daniel (2019). Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ
Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology, 37(16):1412-1423.
DOI: https://doi.org/10.1200/JCO.18.01480
2
original
report
Serum Levels of MicroRNA-371a-3p (M371 Test)
as a New Biomarker of Testicular Germ Cell
Tumors: Results of a Prospective
Multicentric Study
Klaus-Peter Dieckmann, Prof1,2; Arlo Radtke, PhD3; Lajos Geczi, MD, PhD4; Cord Matthies, MD5; Petra Anheuser, MD2;
Ulrike Eckardt, MD6; Jo¨rg Sommer, MD7; Friedemann Zengerling, MD8; Emanuela Trenti, MD9; Renate Pichler, PhD10; Hanjo Belz, MD11;
Stefan Zastrow, MD12; Alexander Winter, MD13; Sebastian Melchior, Prof14; Johannes Hammel, MD14; Jennifer Kranz, MD15;
Marius Bolten, MD16; Susanne Krege, Prof17; Bjo¨rn Haben, MD18; Wolfgang Loidl, MD19; Christian Guido Ruf, MD20;
Julia Heinzelbecker, MD21; Axel Heidenreich, Prof22; Jann Frederik Cremers, MD23; Christoph Oing, MD24; Thomas Hermanns, MD25;
Christian Daniel Fankhauser, MD25; Silke Gillessen, MD26; Hermann Reichegger, MD26; Richard Cathomas, MD27; Martin Pichler, Prof28;
Marcus Hentrich, MD29; Klaus Eredics, MD30; Anja Lorch, Prof31; Christian Wu¨lﬁng, Prof1; Sven Peine, MD24; Werner Wosniok, PhD3;
Carsten Bokemeyer, Prof24; and Gazanfer Belge, PhD3
abstract
PURPOSE Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have
a much higher sensitivity and speciﬁcity than the classic markers of testicular germ cell tumors (GCTs) and are
applicable toward both seminoma and nonseminoma. We sought to conﬁrm the usefulness of this test as a novel
biomarker for GCT.
PATIENTS AND METHODS In a prospective, multicentric study, serum samples of 616 patients with testicular
GCTs and 258 male controls were examined for serum levels of miRNA-371a-3p (miR levels) by quantitative
polymerase chain reaction. The GCT population encompassed 359 patients with seminoma and 257 with
nonseminoma; 371 had clinical stage I disease, 201 had systemic disease, and 46 had relapses. Paired
measurements before and after orchiectomy were performed in 424 patients; 118 with systemic disease had
serial measurements during treatment. miR levels were compared with those of b-human chorionic gonad-
otropin, a-fetoprotein, and lactate dehydrogenase.
RESULTS For the primary diagnosis of GCT, the M371 test showed a sensitivity of 90.1%, a speciﬁcity of 94.0%,
an area under the curve of 0.966 upon receiver operating characteristic analysis, and a positive predictive value
of 97.2%. a-Fetoprotein, b-human chorionic gonadotropin, and lactate dehydrogenase had sensitivities of less
than 50% in seminoma and slightly higher sensitivities in nonseminomas. miR levels were signiﬁcantly as-
sociated with clinical stage, primary tumor size, and response to treatment. Relapses had elevated miR levels
that subsequently dropped to normal upon remission. Teratoma did not express miR-371a-3p.
CONCLUSION The M371 test outperforms the classic markers of GCT with both a sensitivity and a speciﬁcity
greater than 90%. All histologic subgroups, except teratoma, express this marker. The test could be considered
for clinical implementation after further validation.
J Clin Oncol 00. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The serum tumor markers b-human chorionic go-
nadotropin, a-fetoprotein (AFP), and lactate de-
hydrogenase (LDH) became essential tools in the
clinical management of testicular germ cell tumors
(GCTs) in the late 1970s.1,2 Current guidelines rec-
ommend the use of marker measurements for clinical
staging, treatment monitoring, and follow-up of pa-
tients with GCTs.3-6 One major drawback of the
markers, however, is their low overall sensitivity. Only
50% of all GCTs express one of the three markers, and
seminomas lack AFP expression entirely.7,8 Moreover,
LDH expression is also found in several other
diseases.9
The use of serum levels of microRNAs (miRs) from the
miR-371-3 and miR-302/367 clusters as novel GCT
biomarkers was ﬁrst suggested in 2011.10 Generally,
miRs represent small noncoding RNAs that are in-
volved in the epigenetic regulation of gene expres-
sion.11 Previous studies suggested a high sensitivity
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(. 80%) and speciﬁcity (. 90%) of miR-371-3 andmiR-302/
367 for GCTs, with miR-371a-3p proving to be the most
sensitive and most speciﬁc.12-15 The serum levels of this
miR seem to be associated with both clinical stage (CS) and
tumor bulk, with levels dropping to normal with a half-life of
less than 24 hours after the cancer is cured.16,17 Of note,
seminomas were found to express miR-371a-3p in more
than 85% of patients.
The current consensus is that measurements of miR-
371a-3p, also called the M371 test, greatly outperform
the classic markers, and thus, a clinical implementation
of the test seems warranted. However, the available
data are based solely on seven independent small- to
moderate-sized studies with retrospective and pro-
spective modes of patient accrual as well as divergent
miR measurement techniques.13,14,18-22 Moreover, the
majority of patients examined thus far have been in the
early CSs, and only a few had advanced stages. Ac-
cordingly, the body of evidence is both limited by and
open to bias. Therefore, the aim of the current study was
to prospectively evaluate the utility of the M371 test in a
large and representative patient population enrolled from
a large number of European institutions and to involve
various histologies and CSs. In particular, we aimed to
evaluate the diagnostic sensitivity and speciﬁcity of the
test for the primary diagnosis of GCT and to assess its
usefulness for monitoring GCT treatment.
PATIENTS AND METHODS
Study Design and Participants
We performed the prospective study at 37 institutions in
Germany, Austria, Switzerland, Hungary, and Italy be-
tween September 2015 and December 2016 (Appendix
Table A1, online only). A total of 1,364 consecutive male
patients ages 16 to 69 years were recruited. We excluded
490 patients from the study for various reasons (Fig 1).
The ﬁnal study population consisted of 616 patients with
GCT and 258 controls (Table 1). Of the patients with
GCT, 522 provided preoperative samples, and 118 with
systemic disease underwent repeated sampling over the
course of chemotherapy. Controls consisted of 133
males ages 18 to 60 years who presented with non-
malignant testicular disease (NMTD) and 125 healthy
male blood donors of the same ages. The rationale for the
sample size is detailed in the Appendix (online only). The
following patient-related data were registered: date of
blood aspiration, patient age, histology, primary tumor
size, local pathologic stage (pT), CS according to the
Lugano classiﬁcation, serum levels of classic tumor
markers, and treatment received. No information was
available with regard to follow-up examinations of the
included patients. All patients gave informed consent.
The study received ethical approval by A¨rztekammer
Bremen (#301, 2015).
Laboratory Methods
For the measurement of serum miR-371a-3p levels, we
used the method described previously.22 Brieﬂy, RNA was
isolated from cubital vein serum, and then reverse tran-
scription was performed for both miR-371a-3p and the
endogenous control miR-30b-5p to cDNA. Quantitative
polymerase chain reaction was done after preampliﬁcation.
Measurement results were documented as relative quan-
tity (RQ) values. Laboratory details are provided in the
Appendix.
Statistical Methods
A two-sided Mann-Whitney U test was used to assess
differences between two unrelated groups of samples. A
Wilcoxon signed rank test was applied for the comparison of
repeated measurements in individual patients. Receiver
operating characteristic (ROC) analysis was performed with
empirical data, and the optimal cutoff value (the highest
Youden index) was determined. Sensitivity, speciﬁcity,
positive predictive value (PPV), negative predictive value
(NPV), and positive and negative likelihood ratios were
calculated. For the calculation of predictive values, only
patients from four large primary care urologic institutions
were evaluated (see Appendix for rationale). Kernel density
estimation was used as a model of the RQ distribution in an
unlimited sample size. The 95% CIs for discriminative
measurements derived from density estimation were cal-
culated by bootstrapping, with 2,500 simulations. Differ-
ences among categorical data were calculated with an
exact x2 test. To test the association between tumor di-
ameter and miR-371a-3p expression, linear regression was
used. The association of tumor diameter and sensitivity was
tested with logistic regression. RQ values were log-
transformed for kernel density estimation and regression
analysis, whereby values of 0 were assumed to be equiv-
alent to 0.001. Bonferroni correction was applied to the
comparison of miR-371a-3p sensitivity with the classic
markers to adjust for multiple testing. All tests were two-
sided, and signiﬁcance was assumed at P, .05. Statistical
analyses were performed using SPSS version 24 (IBM
Corporation, Armonk, NY) or R version 3.2.3 (The R
Foundation, Vienna, Austria) software.
RESULTS
Evaluation of the M371 Test for Primary Diagnosis of GCT
The median expression of miR-371a-3p was signiﬁcantly
higher in the entire GCT group and in all the CS subgroups
compared with the controls. Patients with CS greater than I
had a higher serum level than those with CS I (all P, .001;
Fig 2A). Seminoma was found to have signiﬁcantly lower
miR-371a-3p values than nonseminoma. However, this
difference was only detectable in CS I patients (Fig 2B).
Teratoma had the lowest expression values of all subtypes
(Fig 2C). Among controls, healthy blood donors and
2 © 2019 by American Society of Clinical Oncology
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patients with NMTD did not have signiﬁcantly different
median RQ values (P = .4).
An ROC analysis that was based on preoperative samples of
the patients with GCT and controls revealed an area under
the curve (AUC) of 0.97 and an optimal cutoff at an RQ of 5
(highest Youden index). On the basis of this cutoff, patients
with GCT could be discriminated from controls with a di-
agnostic sensitivity of 91.8% and a speciﬁcity of 96.1%. After
using kernel density estimation to model the distribution of
RQ values, the AUC was 0.966, whereas the sensitivity was
90.1% and the speciﬁcity 94.0% (Fig 3A). PPV was 97.2%,
and NPV was 82.7%. Table 2 lists a synopsis of all dis-
criminative parameters for the entire group of GCTs and the
subgroups of seminoma and nonseminoma.
The M371 test discriminated patients with localized GCT (CS
I) from those with systemic disease, with an AUC of 0.76
(Appendix Fig A1, online only) and a diagnostic sensitivity
and speciﬁcity of 83.4% and 60.1%, respectively. Com-
parison of the sensitivities of the M371 test (empirical data)
with the classic GCTmarkers (Fig 3B) revealed the sensitivity
of the new test to be signiﬁcantly higher than each of the
classic markers and even the combination of all three. The
superior sensitivity of the M371 test also was found in
subgroup analyses of CSs and the two histologic subgroups
(Figs 3C to F), with the greatest superiority documented in CS
I (Fig 3C) and in seminoma (Fig 3E).
We found a signiﬁcant regression of tumor diameters with
log-transformed miR-371a-3p serum levels (R2 = 0.653;
P, .001) in CS I patients. Subgroup analyses also revealed
this regression in seminoma, mixed nonseminoma, and
embryonal carcinoma (R2 = 0.686, 0.745, and 0.619,
respectively; each P , .001; Fig 4A), with much higher
slopes of the regression curves in mixed nonseminoma and
embryonal carcinoma than in seminoma (Fig 4A). Ac-
cordingly, the sensitivity of miR-371a-3p for detecting
seminoma was signiﬁcantly lower in the two lowest tumor
size categories (# 9 mm and 10 to 19 mm) than in the
larger categories (P , .001; Fig 4B). In nonseminoma, no
divergent sensitivities were found among the various size
categories (P = .8; Fig 4C). Localized tumors (pT1) had
signiﬁcantly lower median miR levels than advanced local
stages (. pT1) among CS I patients (R2 = 0.664; P, .001;
Appendix Fig A2, online only).
miR-371a-3p Levels in Treatment Monitoring
Paired measurements of miR-371a-3p in 424 patients
before and after orchiectomy revealed a signiﬁcant drop in
miR expression levels in both local and systemic disease
(P , .001 for each category; Fig 5A). Of the CS I patients,
91.77% had decreased levels after surgery as opposed to
82.41% of patients with metastases (P = .008 for pro-
portions of decreasing levels). Appendix Figure A3 (online
only) shows additional details.
Enrolled
possibly eligible patients 
(n = 1,364)
Patients with 
serum samples examined 
(n = 874)
Patients with GCTs
eligible for study        (n = 616)
Evaluated for primary 
diagnosis                     (n = 522)
Evaluated before and after 
    chemotherapy     (n = 118)
Evaluated for relapse of GCT 
                                          (n = 46)   
Patients
without GCTs
(controls) eligible
for study 
(n = 258)   
Excluded
Missing serum samples
No clinical data
Inappropiate age
Other
(n = 490)
(n = 314)
(n = 132)
(n = 36)
 (n = 8)
FIG 1. Study proﬁle. The diagram shows the
selection process of patient enrollment. GCT,
germ cell tumor.
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Serial measurements of miR-371a-3p levels during che-
motherapy in 118 patients with systemic disease revealed a
signiﬁcant decrease after the ﬁrst cycle of therapy. In the 70
patients with CS IIa,b disease, subsequent cycles did not
cause a further signiﬁcant decrease in miR levels (Fig 5B).
In CS III patients (n = 46), we observed another signiﬁcant
decrease in miR levels after the second cycle of chemo-
therapy, with no further signiﬁcant changes with additional
courses (Fig 5C). In two patients with mediastinal GCTs,
miR levels dropped upon treatment in the same manner as
in CS III patients (data not shown). Two patients had a fatal
outcome and achieved strikingly elevated miR levels upon
progression (Figs 5B and C as denoted with a †). Patients in
the International Germ Cell Cancer Collaborative Group
good prognosis category had signiﬁcantly lower miR-371a-
3p median values than those in the poor prognosis category
(P = .04; Appendix Fig A4, online only).
miR-371a-3p Levels in Patients With Relapsed Disease
Patients with relapsed disease (n = 46) had a signiﬁcantly
higher median serummiR level than controls (P, .001; Fig
2D). Elevated levels were found in 38 patients, which
corresponded to a sensitivity of 82.6%, a speciﬁcity of
96.1%, and an AUC of 0.921 for relapse detection. Serial
measurements during treatment revealed signiﬁcant de-
creases in miR levels in 28 of 29 patients (Fig 5D).
DISCUSSION
This study provides a considerable body of evidence that
supports the usefulness of miR-371a-3p serum levels as a
new biomarker of GCTs. Five features of the M371 test are
noteworthy: The test has a 90.1% sensitivity and a 94.0%
speciﬁcity for establishing the primary diagnosis of GCT; it is
relevant for the two main histologic subgroups of GCT; miR
serum levels correlate with primary tumor size, local stage,
and CSs; miR levels mirror treatment-related disease
changes; and miR levels are elevated in recurrences.
According to current guidelines, the classic tumor markers
are not adequately effective for assessing primary diagnosis
of GCT because of their low sensitivity and speciﬁcity.4-6
Currently, clinical and ultrasound examination followed by
surgical exploration represent the mainstays of diagnosing
GCT. Scrotal magnetic resonance imaging is a second-line
TABLE 1. Clinical Data of Participants
Participants (n = 874), No. (%)
Patients With GCTs* Controls†
Characteristic CS I CS II CS III Relapse Mediastinal NMTD Healthy Male
No. of participants 371 (60.2) 131 (21.3) 70 (11.4) 46 (7.5)‡ 2 (0.3) 133 (51.6) 125 (48.4)
Seminoma histology 259 (69.8) 66 (50.4) 18 (25.7) 16 (34.8) — — —
Nonseminoma histology
Mixed GCT 74 (19.9) 44 (33.6) 35 (50.0) 23 (50.0) 1 (50.0) — —
Embryonal carcinoma 29 (7.8) 19 (14.5) 11 (15.7) 1 (2.2) 1 (50.0) — —
Yolk sac tumor 3 (0.8) 1 (0.8) 2 (2.9) — — — —
Choriocarcinoma — — 1 (1.4) 2 (4.3) — — —
Teratoma 6 (1.6) 1 (0.8) 3 (4.3) 4 (8.7) — — —
Median tumor diameter, mm (IQR) 30.0 (17.0-45.0) 38.5 (25.0-53.0) 48.0 (33.5-61.5) — — — —
pT stage
pT1 242 (65.2) 51 (38.9) 16 (22.9) — — — —
pT2 101 (27.2) 58 (44.3) 24 (34.3) — — — —
pT3 17 (4.6) 14 (10.7) 17 (24.3) — — — —
No clinical data available 11 (3.0) 8 (6.1) 13 (18.6) — — — —
IGCCCG prognosis
Good — 102 (77.9) 32 (45.7) 26 (56.5) — — —
Intermediate — 8 (6.1) 14 (20.0) 7 (15.2) — — —
Poor — 3 (2.3) 20 (28.6) 6 (13.0) 2 (100.0) — —
No clinical data available — 18 (13.7) 4 (5.7) 7 (15.2) — — —
Abbreviations: CS, clinical stage; GCT, germ cell tumor; IGCCCG, International Germ Cell Cancer Collaborative Group; IQR, interquartile range; NMTD,
nonmalignant testicular disease; pT, pathologic tumor stage.
*n = 616 (70.5%); median age, 35.0 years (IQR, 29.0-44.3 years).
†n = 258 (29.5%); median age, 35.0 years (IQR, 26.0-47.0 years).
‡Four patients with relapse also had primary tumors; therefore, the percentage adds up to . 100%.
4 © 2019 by American Society of Clinical Oncology
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diagnostic tool; surveillance can be used in incidentally
detected small masses.23,24 The high discriminative power
of the test is evidenced by an AUC of 0.966 in the ROC
analysis, the overall accuracy of 93.2%, and particularly the
very high positive likelihood ratio of 23.675 (Table 2).
Accordingly, in cases that remain indeterminate despite
evaluation with all guideline-recommended examinations,
the M371 test may add useful information for clinical de-
cision making before surgery.16,25 One foreseeable weak-
ness of the test could be in the detection of pure
seminomas with sizes of less than 1 cm because only 59%
of these express the marker (Fig 4B).
Serum levels of miR-371a-3p signiﬁcantly correlate with CS
of GCTs (Fig 2A) and with the size of the primary tumor (Fig
4). The most probable explanation for this ﬁnding would be
a close correlation between miR levels and the amount of
tumor (ie, number of cells) present. In fact, this feature is
one of the six prerequisites an ideal tumor marker is
supposed to have.2,26 Accordingly, the M371 test can
discriminate locally conﬁned from metastasized disease
with a sensitivity of 83.4% but with a speciﬁcity of only
60.1%. Computed tomography, the mainstay of clinical
staging, has an overall accuracy of 82% with a sensitivity of
59% in detecting retroperitoneal metastases.5,6,27,28
Therefore, even in conjunction with the analysis of clas-
sic markers, some cases remain unresolved. TheM371 test
might aid in assessing the correct CS.
In contrast to the classic markers, both of the two main
histologic subgroups expressed miR-371a-3p with fre-
quencies of approximately 90%, with the exception of
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FIG 2. Relative expression of microRNA (miR)-371a-3p in patients with germ cell tumors (GCTs) and controls. (A) Box plots that represent miR-
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teratoma. In line with previous serum-14,22,29 and tissue-
based studies,30,31 we found CS I patients with pure
teratoma to have very low to zero detectable miR-371a-
3p expression. Of note, patients with metastasized ter-
atoma displayed elevated miR expression (Fig 2C).
Admixtures of other GCT components might have caused
the elevation in metastatic teratoma. Nonseminomas
have a signiﬁcantly higher median serum level than
seminomas in locally conﬁned disease, and this differ-
ential expression has been reported previously but not
unanimously.13,14 On the basis of the evidence that
suggests that the miR-371-3 cluster is expressed
primarily by undifferentiated stem cells,32,33 it has been
hypothesized that the close biologic association between
embryonal carcinoma and undifferentiated stem cells
results in higher expression of miR-371a-3p in non-
seminoma than in the more differentiated seminoma and
even less in the well-differentiated teratoma.22 Con-
trasting results were reported from a tissue-based ex-
amination wherein seminoma was found to have
signiﬁcantly higher expression of miR-371a-3p than
nonseminoma.30 However, these ﬁndings must be
assessed with caution because tissue miR levels do not
correlate with serum levels.18
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FIG 4. Dependency of microRNA (miR)-371a-3p expression and sensitivity on tumor diameter. (A) Scatterplot that represents the relationship between
tumor diameter and the miR-371a-3p expression of clinical stage (CS) I seminoma (circles; n = 259), CS I mixed nonseminoma (squares; n = 74), and CS I
embryonal carcinomas (triangles; n = 29). Regression lines are depicted for all three groups in the corresponding color. The dashed line represents the
cutoff value. (B) Sensitivity in various categories of tumor diameter of CS I seminoma. (C) Sensitivity in various categories of tumor diameter of CS I
nonseminoma. Error bars indicate 95% CI.
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An important drawback of the markers AFP, b-human
chorionic gonadotropin, and LDH is their overall low sen-
sitivity and low speciﬁcity, particularly in the lower CSs.34,35
The median miR-371a-3p expression rates are likewise
lower in early stages than in advanced disease; however,
these differences are small and range between sensitivities
of 86.7% and 98.4%. Hence, the M371 test exceptionally
outperforms the classic markers at all CSs (Fig 3). Clinically,
this feature is most relevant toward the management of
seminomas, where more useful tools for the monitoring of
patients under surveillance are needed.36
The hypothesis that serum miR-371a-3p levels correlate
with tumor bulk is supported by our observation that serum
levels decreased in response to therapy (Fig 5). After
orchiectomy, 91.8% of all CS I patients displayed de-
creased serum levels, with the majority dropping to within
the normal range. The reason why a small proportion of
patients had inadequate decreases of miR levels after
orchiectomy remains unresolved because there were no
follow-up data available in this study. Occult metastatic
disease is the most probable hypothesis to explain this
ﬁnding.
A
Re
la
tiv
e 
m
iR
-3
71
a-
3p
 E
xp
re
ss
io
n
*
CS I
1,000,000
100,000
10,000
1,000
100
10
1
0
Pre Post
*
CS II
Pre Post
*
CS III
Pre Post
Re
la
tiv
e 
m
iR
-3
71
a-
3p
 E
xp
re
ss
io
n
B
*
†
100,000
10,000
1,000
100
10
1
0
Pre-
Cycle 1
Pre-
Cycle 2
Pre-
Cycle 3
Pre-
Cycle 4
Post-
Treatment
*
D
Re
la
tiv
e 
m
iR
-3
71
a-
3p
 E
xp
re
ss
io
n
1,000,000
100,000
10,000
1,000
100
10
1
0
At Relapse Post-Treatment
*
C
Re
la
tiv
e 
m
iR
-3
71
a-
3p
 E
xp
re
ss
io
n
*
†
100,000
10,000
1,000
100
10
1
0
Pre-
Cycle 1
Pre-
Cycle 2
Pre-
Cycle 3
Pre-
Cycle 4
Post-
Treatment
FIG 5. Post-treatment decrease of microRNA (miR)-371a-3p. (A) Decrease of miR-371a-3p expression after surgical removal of the primary tumor in clinical
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In systemic disease, orchiectomy results in a decrease in
miR levels in many patients, although in most, the decrease
does not reach the normal range. Marker production by
metastatic tissue is the most likely explanation for this
observation. Of note, a few CS II patients dropped to normal
miR levels postoperatively (Fig 5A). Although the in-
terpretation of this ﬁnding is hampered by the lack of follow-
up information, a tempting hypothesis would be clinical
overstaging in these patients, which would be in accord
with surgical studies that documented staging error in
approximately 20% of CS II patients.37 Serial miR mea-
surements in patients with systemic disease revealed sig-
niﬁcant decreases upon chemotherapy. Of note, the
majority of CS II patients dropped to normal levels after only
one cycle, with insigniﬁcant further decreases after addi-
tional courses (Fig 5B). Because miR levels correlate with
tumor bulk, this ﬁnding could possibly allow for the hy-
pothesis that the cumulative chemotherapy dosage re-
quired for low-volume disease deserves reconsideration.
In CS III patients, there is also a highly signiﬁcant decrease
in miR levels after the ﬁrst cycle of chemotherapy, with the
second cycle producing further signiﬁcant decreases. At
treatment completion, the majority of patients with me-
tastases have normal miR levels. Treatment failure was
documented clinically in a few patients, and was accom-
panied by rising miR levels. The two patients with a lethal
outcome displayed increasing miR levels with disease
progression and reached the highest values of all patients.
Recently, two independent investigations likewise showed
signiﬁcant decreases of serum M371 levels in patients with
metastases who received chemotherapy, which supports
the value of this marker for monitoring treatment
outcome.29,38 Moreover, the Princess Margaret Group
demonstrated the value of the marker in identifying viable
residual cancer in postchemotherapy residual masses and
conﬁrmed the lack of M371 expression in teratoma.29
The M371 test has an 82.6% sensitivity at an AUC of 0.921
to detect relapse. One reason why the test may detect
recurrences at a somewhat lower sensitivity than primary
GCT might be because miR-negative subtypes like tera-
toma and somatic-type malignancy occur with higher fre-
quency upon recurrence.27,39,40 Nevertheless, the M371
test may have the potential to detect recurrences at an early
stage in a substantial number of patients as has been
recently documented.16,19,25,41 MiR levels likewise de-
creased upon treatment of relapse as they did in metas-
tasized primary disease.
Limitations of the current study stem from the lack of
clinical information on patient follow-up because several
individual sequences of miR levels could not be sufﬁciently
charted. In addition, histologic work-ups of orchiectomy
specimens were performed by local pathologists without
central pathology review, which involve minor uncertainties
with regard to the differential assessment of nonseminoma.
Among the serial measurements of patients with metas-
tases, not all the patients had undergone measurements
after each chemotherapy cycle. Accordingly, some missing
measurement points may have reduced statistical power.
All serum samples were deep frozen for several months
until measurement; thus, some sample deterioration may
have occurred in the meantime.42 Strengths of the study
involve the multicentric, multinational design, which
resulted in a minimal selection bias. In addition, laboratory
measurement techniques were uniformly used for all
samples analyzed.
In conclusion, the current study strongly conﬁrms previous
data with regard to the usefulness of the M371 test as a new
serum biomarker of GCT that is informative in both semi-
noma and nonseminoma. Because of its high sensitivity
and speciﬁcity, this test involves the potential of simplifying
clinical pathways of the management of GCT, although
further validation in an independent cohort is needed.
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APPENDIX Methods
Rationale for sample size. In this study, we aimed to conduct
several subanalyses to conﬁrm the usefulness of the M371 test as a
germ cell tumor (GCT) serum biomarker. The most important analysis
was the comparison of the sensitivity of M371 with that of the classic
markers in various histologic subgroups. For this purpose, we used the
data available from our previous study on the M371test22 and de-
termined the effect size w for several comparisons. The smallest effect
size was found when all classic markers (combined) were compared
with M371 in the subgroup of nonseminoma (w = 0.37). To achieve
this effect size with a power of at least 0.95 and an a-level of .01 (as a
result of Bonferroni correction) in a x2 test, we would need 90 patients
with nonseminoma for analysis of preoperative M371 values. With the
assumption of a proportion of nonseminoma of at least 30% among the
entire GCT population, we would need to enroll approximately 300
study patients to obtain sufﬁcient numbers with nonseminoma for the
preoperative analysis.
Furthermore, we aimed to analyze a meaningful number of patients
with pure GCT histologies, particularly pure embryonal carcinoma, to
validate the very high M371 expression rates in these subgroups.
Because only 10% of GCTs reportedly represent pure embryonal
carcinomas (Ulbright TM: Mod Pathol 18:S61-S79, 2005), we decided
to increase the sample number to 500 patients to obtain approximately
50 pure embryonal carcinomas for analysis.
The next important analysis was the monitoring of M371 serum values
over the course of chemotherapy. Again, the sample size was esti-
mated on the basis of the data from our previous study, and it became
evident that we would need at least 90 patients to detect a similar effect
size between chemotherapy cycles at a power of 0.95 and an a-level of
.05 with a Wilcoxon signed rank test. We therefore aimed to enroll at
least 100 patients to provide repeat serum samples taken over the
course of chemotherapy.
Finally, we assumed that a signiﬁcant proportion of the patients
originally included would have to be excluded from study in the end
because of missing clinical data, which is a common problem in large
multicentric clinical investigations. We therefore increased the cal-
culated number of patients to be enrolled by one third to account for
dropouts.
Exclusion criteria for patients. The following reasons were ap-
plied to exclude participants from the study: age of participant outside
the range of 16 to 69 years, substantial clinical data missing (eg,
histology, clinical stage), and missing samples at important time points
(eg, starting samples in patients treated with chemotherapy).
Rationale for selection of institutions for calculation of
predictive values. Principally, to calculate the positive predictive
values (PPVs) and negative predictive values (NPVs), a study population
that consisted of both patients with and without disease is needed.
However, among the participating institutions of the current study, there
were marked imbalances with regard to the ratio of patients with tumors
and those without tumors (the prevalence). Some of the participating
clinics represented tertiary care centers rather than primary care in-
stitutions and, therefore, contributed few to no patients without tumors.
In addition, there were more patients with tumors than controls who had
to be excluded from the study because of missing clinical data.
To have a largely homogeneous study population for calculating PPV
and NPV, we decided to use four particular institutions (Albertinen-
Krankenhaus Hamburg, Asklepios Klinik Altona, Bundeswehrkran-
kenhaus Hamburg, and Klinikum Bremen-Mitte), which were selected
because they represented primary urologic care units and all con-
tributed substantial numbers of both patients with GCTs and controls.
In fact, the majority of study controls with nonmalignant testicular
disease (90 of 133) were enrolled by these four institutions. Moreover,
only very few of these particular controls had to be excluded. The study
population for calculating predictive values thus encompassed 155
patients with GCTs and 90 controls without tumors. The disease
prevalence rate was 63.3% (95% CI, 56.9% to 69.3%).
Laboratory Methods
Handling of blood samples. Whole-blood samples were pro-
cessed to serum in local hospital laboratories by centrifugation at
2,5003 g. Serum aliquots were then stored at 280°C. The frozen
samples were shipped to the central study laboratory at the University
of Bremen where all study material was kept at 280°C until ﬁnal
processing.
Measurement of microRNA-371a-3p in serum. For relative
quantiﬁcation of miRNA (miR)-371a-3p in serum, RNA was isolated
from 200mL cubital vein serum using themiRNeasy Mini Kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instructions. cDNA
synthesis was conducted with the TaqMan miRNA Reverse Tran-
scription Kit (Thermo Fisher Scientiﬁc, Schwerte, Germany). Stem-
loop primers for miR-371a-3p and the endogenous control miR-30b-
5p were part of the corresponding TaqMan assays (assay identiﬁers
002124 and 000602, respectively; Thermo Fisher Scientiﬁc). The
cDNA was pre-ampliﬁed in a standard polymerase chain reaction
(PCR) using TaqMan assays in a 1:100 dilution and a hot start master
mix (Jena Bioscience, Jena, Germany) with the following temperature
proﬁle: 1 minute at 95°C followed by 14 cycles of 15 seconds at 95°C
and 4 minutes at 60°C. Thereafter, the miRNA was quantiﬁed in 40
cycles of quantitative PCR on a 7500 Fast Real-Time PCR System
(Thermo Fisher Scientiﬁc) with the aforementioned TaqMan assay and
FastStart Universal Probe Master Mix (Roche, Mannheim, Germany).
The temperature proﬁle was as follows: 10 minutes at 95°C followed by
40 cycles of 15 seconds at 95°C and 1 minute at 60°C. The relative
quantity of miR-371a-3p was calculated according to the DDCT
method. Each sample was measured in triplicate. Control measure-
ments without reverse transcription were run for every sample, and no-
template controls were run for every experiment.
Repeat measurements. Repeat measurements were performed on
six serum samples with ﬁve repetitions each. For each sample,
the standard deviation of the ﬁve measurement values was cal-
culated. All six samples together showed an average standard
deviation of quantitation cycle values of 0.542 and 0.45 for miR-
371a-3p and the endogenous control miR-30b, respectively. The
relative quantity values thus involve an average standard deviation
of 19.25%.
Measurement of traditional tumor markers. Serum levels of
b-human chorionic gonadotropin, a-fetoprotein, and lactate de-
hydrogenase were measured according to standard laboratory
guidelines in local hospital laboratories.3
© 2019 by American Society of Clinical Oncology
Dieckmann et al
Downloaded from ascopubs.org by Universitaet Zuerich on May 27, 2019 from 144.200.017.042
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
1.00.80.60.40.20.0
1.0
0.8
0.6
0.4Se
ns
iti
vi
ty
1 – Specificity
0.2
FIG A1. Receiver operating characteristic curve that discriminates
clinical stage I patients (n = 371) from patients with systemic
disease (n = 151) at an area under the curve of 0.76. A relative
quantity cutoff value of 308 (highest Youden index) resulted in a
sensitivity of 83.4% and a speciﬁcity of 60.1%.
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FIG A2. Linear regression analysis revealed an association of
microRNA (miR)-371a-3p expression with pathologic tumor (pT)
stage (R2 = 0.664; P , .001).
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FIG A4. Box plots of microRNA (miR)-371a-3p expression in patients
with systemic disease before chemotherapy. Patients with In-
ternational Germ Cell Cancer Collaborative Group (IGCCCG) poor
prognosis have signiﬁcantly higher levels than patients with good
prognosis (P = .04).
CS I patients with pre- and
postoperative measurements
(n = 316)
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FIG A3. Diagram showing results of paired measurements of microRNA (miR)-371-a-3p levels (before and after
orchiectomy) in clinical stage (CS) I patients. (*) Two of the nine patients had elevated levels of classic markers
before and after surgery.
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TABLE A1. Alphabetical Listing of Contributing Institutions
1 Albertinen-Krankenhaus Hamburg, Department of
Urology, Hamburg, Germany
2 Ameos Klinikum Geestland, Department of Urology,
Geestland, Germany
3 Asklepios Klinik Altona, Department of Urology, Hamburg,
Germany
4 Bundeswehrkrankenhaus Hamburg, Department of
Urology, Hamburg, Germany
5 Bundeswehrzentralkrankenhaus Koblenz, Department of
Urology, Koblenz, Germany
6 Centrum fu¨r Reproduktionsmedizin und Andrologie,
Mu¨nster, Germany
7 Diakonissenkrankenhaus Dessau, Department of Urology,
Dessau-Roßlau, Germany
8 Helios Kliniken Schwerin, Department of Urology,
Schwerin, Germany
9 Kaiser Franz Josef Spital Wien, Department of Urology,
Wien, Austria
10 Kantonsspital Graubu¨nden, Department of Oncology,
Chur, Switzerland
11 Kantonsspital St. Gallen, Department of Oncology, St
Gallen, Switzerland
12 Klinikum Essen-Mitte Huyssenstiftung, Department of
Urology, Essen, Germany
13 Klinikum Ingolstadt, Department of Urology, Ingolstadt,
Germany
14 Klinikum Oldenburg, Department of Urology, Oldenburg,
Germany
15 Krankenhaus Barmherzige Bru¨der, Department of
Urology, Trier, Germany
16 Krankenhaus Bozen, Su¨dtiroler Sanita¨tsbetrieb,
Department of Urology, Bolzano, Italy
17 National Institute of Oncology, Budapest, Hungary
18 Ordensklinikum Barmherzige Schwestern, Department of
Urology, Linz, Austria
19 Rotkreuzklinikum Mu¨nchen, Department of Oncology,
Munich, Germany
20 St Antonius Hospital, Department of Urology, Eschweiler,
Germany
21 St Elisabeth Krankenhaus Leipzig, Department of Urology,
Leipzig, Germany
22 St Franziskus Hospital Lohne, Department of Urology,
Lohne Germany
23 St Marienkrankenhaus Ahaus, Department of Urology,
Ahaus, Germany
24 Universita¨tsklinikum Carl Gustav Carus, Department of
Urology, Dresden, Germany
25 Universita¨tsklinikum Du¨sseldorf, Department of Urology,
Du¨sseldorf, Germany
26 Universita¨tsklinikum Eppendorf, Department of Medical
Oncology, Hamburg, Germany
(continued in next column)
TABLE A1. Alphabetical Listing of Contributing Institutions
(continued)
27 Universita¨tsklinikum Eppendorf, Institute of Transfusion
Medicine, Hamburg, Germany
28 Universita¨tsklinikum Graz, Department of Oncology, Graz,
Austria
29 Universita¨tsklinikum Ko¨ln, Department of Urology,
Cologne, Germany
30 Universita¨tsklinikum Saarland, Department of Urology,
Homburg, Germany
31 Universita¨tsspital Zu¨rich, Department of Urology, Zurich,
Switzerland
32 University Innsbruck, Department of Urology, Innsbruck,
Austria
33 University of Ulm, Department of Urology, Ulm, Germany
34 Vivantes Klinikum am Urban, Department of Oncology,
Berlin, Germany
35 Vivantes Klinikum Neuko¨lln, Department of Oncology,
Berlin, Germany
36 Zeisigwaldkliniken Chemnitz, Department of Urology,
Chemnitz, Germany
37 Zentralklinikum Bremen, Department of Urology, Bremen,
Germany
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